Search results
Axsome maintains Buy stock rating amid short report claims By Investing.com
Investing.com· 3 days agoOn Tuesday, Guggenheim reaffirmed its Buy rating on Axsome Therapeutics (NASDAQ:AXSM), despite a...
With A Similar Revenue Base, Is Johnson & Johnson A Better Pick Despite The 30% Fall In Tesla Stock...
Forbes· 2 days agoIn this case, although these companies are from different sectors, they share a similar revenue base...
Sunday Reads: Apple Fest and hot dogs
Quartz· 5 days agoHunter Biden is on trial, his dad shut the border to migrants seeking asylum, a handful of remaining veterans commemorated the 1944 D-Day landings, and...
Abbott Laboratories's Options: A Look at What the Big Money is Thinking - Abbott Laboratories...
Benzinga· 4 days agoProducts include pacemakers, implantable cardioverter defibrillators, neuromodulation devices...history for Abbott Laboratories, it's now appropriate to focus on the company
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 4 days ago(“GoodRx” or “the Company”) (NASDAQ: GDRX) and certain of its officers. This lawsuit seeks to recover damages against Defendants...violations of the federal securities laws ...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against...
Morningstar· 4 days ago(NASDAQ: BIIB), Charge Enterprises (NASDAQ: CRGEQ), and Fastly, Inc. (NYSE: FSLY). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Biogen is a global ...
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class...
Morningstar· 4 days ago(NASDAQ: BIIB)? Did you lose money in your investment in Biogen Inc.? Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased ...
